Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.52 USD
Change Today +0.12 / 30.00%
Volume 2.5K
LIXT On Other Exchanges
As of 12:56 PM 11/27/15 All times are local (Market data is delayed by at least 15 minutes).

lixte biotechnology holdings (LIXT) Snapshot

Previous Close
Day High
Day Low
52 Week High
11/27/15 - $0.52
52 Week Low
02/23/15 - $0.07
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

lixte biotechnology holdings (LIXT) Related Businessweek News

No Related Businessweek News Found

lixte biotechnology holdings (LIXT) Details

Lixte Biotechnology Holdings, Inc., a development stage company, researches and develops treatments for human cancers and other common non-malignant diseases. It develops anti-cancer drugs for life-threatening diseases using biomarker technology. The company focuses on the development of protein phosphatase inhibitors, such as the LB-100 series of compounds; and histone deacetylase inhibitors, including the LB-200 series of compounds for the treatment of cancer, as well as in the prevention and treatment of neurodegenerative diseases. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in East Setauket, New York.

lixte biotechnology holdings (LIXT) Top Compensated Officers

Founder, Chairman of the Board, Chief Executi...
Total Annual Compensation: $60.0K
Compensation as of Fiscal Year 2014.

lixte biotechnology holdings (LIXT) Key Developments

Lixte Biotechnology Holdings, Inc. Announces Novel Protein Phosphatase 2A Inhibitor Associated with Stabilization of Several Types of Cancer Without Dose-Limiting Toxicity

Lixte Biotechnology Holdings, Inc. announced that in an ongoing Phase I trial its lead anti-cancer compound, LB-100, was associated with stabilization of a variety of advanced cancers that had been progressing despite extensive prior treatment. The results were presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference, Boston, on November 6. A total of 21 patients received LB-100 for 3-consecutive days in 3-week cycles. Nine of these patients had stabilization of their disease without significant toxicity. One patient with pancreatic cancer received 14 cycles of LB-100 (42 weeks); one with thymoma, 9 cycles; one with testicular and one with carcinoid of the lung, 5 cycles; two with ovarian, 3 and 6 cycles; and one with NSCLC and one with duodenal cancer, 3 cycles. The average number of cycles received at the last four evaluable dose levels of LB-100 was 4.8 (14.4 weeks). In a study by Mansfield et al (2015 JCO 33[15] suppl:2567), the average number of cycles of a new drug in 51 NCI-sponsored Phase 1 trials conducted from 1994-2014 involving 1,841 patients was 2.0 (6-8 weeks).

Lixte Biotechnology Holdings, Inc. Auditor Raises 'Going Concern' Doubt

Lixte Biotechnology Holdings, Inc. filed its 10-K on Mar 27, 2015 for the period ending Dec 31, 2014. In this report its auditor, Weinberg & Company, P.A., gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Lixte Biotechnology Holdings, Inc. Announces Expansion of Clinical Sites for its Phase I Trial of Lead Anti-Cancer Compound, LB-100

Lixte Biotechnology Holdings, Inc. announced that the number of clinical sites where its Phase I trial of Lixte's lead compound, LB-100, is being conducted, has been expanded from 1 to 5 institutions. The company said that, the initial trial was planned to be completed at a single site. Accrual of patients, however, was slower than projected. The recent addition of 4 more active clinical oncologic research sites has already enhanced the rate of accrual with patient entry at the 5th planned dose escalation to be completed this month. The original time-line for completion of both parts of this 2-part trial was June 30, 2015. The estimated time to completion of Part 1 of the trial, the determination of dose and safety of LB-100 alone (maximum tolerated dose (MTD)), is now projected to be the 2nd quarter of 2015 and completion of Part 2, determination of the MTD of LB-100 combined with docetaxel, the 2nd quarter of 2016. The estimated cost for completion of both Part 1 and 2 is $2,615,000 versus the original projection of $2,038,000. The ultimate cost may vary depending on such factors as the number and rate of accrual of patients. The increase in cost is for management of the study, predominantly the monitoring of the additional new sites over a longer period of time.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LIXT:US $0.52 USD +0.12

LIXT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for LIXT.
View Industry Companies

Industry Analysis


Industry Average

Valuation LIXT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact LIXTE BIOTECHNOLOGY HOLDINGS, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at